GBT
Mar 18, 2021
GBT strikes a deal with Sanofi; Lilly’s IL-23 inhibitor shows promise; Glooko raises $30M; FDA uplifts hold on Solid’s DMD gene therapy
Global Blood Therapeutics strikes a deal with Sanofi for sickle cell disease programs As Global Blood Therapeutics works to bring its sickle cell disease drug, Oxbryta, to younger patients, the company is reinforcing its pipeline with a pair of early-stage programs from Sanofi. In exchange for the global righ...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
